Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable securities, and expects its cash burn for the full year 2025 will be approximately $55.0 million to $65.0 million. Fulcrum also expects that its cash, cash equivalents, and marketable securities as of September 30, 2024 will be sufficient to fund its current operating requirements into at least 2027.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Is FULC a Buy, Before Earnings?
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
- Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
- Fulcrum Therapeutics to reduce workforce from 80 to 51 full-time employees
- Largest borrow rate increases among liquid names